Search Results - "SCOLDING, N"

Neurosarcoidosis: a study of 30 new cases by Joseph, F G, Scolding, N J

“…Methods:The frequency, nature, relationship to systemic features, value of investigation findings and outcomes for a cohort of patients with neurosarcoidosis…”
Get full text

Neurosarcoidosis: a clinical approach to diagnosis and management by Ibitoye, Richard T., Wilkins, A., Scolding, N. J.

“…Sarcoidosis is a rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. Our understanding of…”
Get full text

Amyloid cerebrovasculopathies by Scolding, N J

Get more information

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs by Bertsias, G K, Ioannidis, J P A, Aringer, M, Bollen, E, Bombardieri, S, Bruce, I N, Cervera, R, Dalakas, M, Doria, A, Hanly, J G, Huizinga, T W J, Isenberg, D, Kallenberg, C, Piette, J C, Schneider, M, Scolding, N, Smolen, J, Stara, A, Tassiulas, I, Tektonidou, M, Tincani, A, van Buchem, M A, van Vollenhoven, R, Ward, M, Gordon, C, Boumpas, D T

“…To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. The authors…”
Get more information

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort by Willis, MD, Harding, KE, Pickersgill, TP, Wardle, M, Pearson, OR, Scolding, NJ, Smee, J, Robertson, NP

“…Background: Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns remain about its use since long-term studies of adverse events…”
Get full text

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients by Joseph, F G, Hirst, C L, Pickersgill, T P, Ben-Shlomo, Y, Robertson, N P, Scolding, N J

“…Objective:Oligoclonal band (OCB) negative multiple sclerosis (MS) is well recognised but uncommon, studied in only a few usually small case series. These…”
Get full text

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort by Cossburn, M, Pace, A A, Jones, J, Ali, R, Ingram, G, Baker, K, Hirst, C, Zajicek, J, Scolding, N, Boggild, M, Pickersgill, T, Ben-Shlomo, Y, Coles, A, Robertson, N P

“…To define the rate, timing, and clinical risk factors for the development of autoimmune disease (AID) after alemtuzumab treatment for multiple sclerosis (MS)…”
Get full text

Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal‐appearing white matter by Hares, K., Redondo, J., Kemp, K., Rice, C., Scolding, N., Wilkins, A.

“…Aims Understanding the causes of axonal pathology remains a key goal in the pursuit of new therapies to target disease progression in multiple sclerosis (MS)…”
Get full text

Adult stem cells and multiple sclerosis by Scolding, N.

“…Multiple sclerosis (MS) is a common neurological disease and a major cause of disability, particularly affecting young adults. It is characterized by patches…”
Get full text

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases by Elovaara, I., Apostolski, S., Van Doorn, P., Gilhus, N. E., Hietaharju, A., Honkaniemi, J., Van Schaik, I. N., Scolding, N., Soelberg Sørensen, P., Udd, B.

“…Despite high‐dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune‐mediated neurological diseases, the consensus on its…”
Get full text

KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis by Hares, Kelly, Kemp, K., Loveless, S., Rice, C. M., Scolding, N., Tallantyre, E., Robertson, N., Wilkins, A.

“…There is increasing interest in the development of multiple sclerosis (MS) biomarkers that reflect central nervous system tissue injury to determine prognosis…”
Get full text

Neurosarcoidosis: a clinical approach to diagnosis and management by Ibitoye, Richard T., Wilkins, A., Scolding, N. J.

Get full text

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases by Elovaara, I, Apostolski, S, van Doorn, P, Gilhus, N E, Hietaharju, A, Honkaniemi, J, van Schaik, I N, Scolding, N, Soelberg Sørensen, P, Udd, B

“…Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its…”
Get full text

Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? by Brittain, Gavin, Coles, Alasdair J, Giovannoni, G, Muraro, Paolo Antonio, Palace, Jacqueline, Petrie, Jennifer, Roldan, Elisa, Scolding, N J, Snowden, John A, Sharrack, Basil

“…In carefully selected patients, autologous haematopoietic stem cell transplantation (HSCT) is a safe, highly effective and cost-saving treatment modality for…”
Get more information

Neuro-Behçet's disease in Caucasians: a study of 22 patients by Joseph, F. G., Scolding, N. J.

“…Several analyses of the neurological features of Behçet's disease (BD) have concluded that there are significant racial differences in its clinical expression…”
Get full text

Factors affecting mortality after traumatic brain injury in a resource‐poor setting by Okidi, R., Ogwang, D. M., Okello, T. R., Ezati, D., Kyegombe, W., Nyeko, D., Scolding, N. J.

“…Background Traumatic brain injury (TBI) is a major cause of long‐term disability and economic loss to society. The aim of this study was to assess the factors…”
Get full text

Sarcoidosis of the nervous system by Joseph, F G, Scolding, N J

“…Although sarcoidosis is rarely confined to the nervous system, any neurological features that do occur frequently happen early in the course of the disease…”
Get more information

Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum by KEMP, Kevin, GRAY, Elizabeth, WILKINS, Alastair, SCOLDING, Neil

“…A major conceptual consideration in both endogenous and therapeutic central nervous system repair is how damaged (or senescent) neurons, given their often…”
Get full text

Protecting axons in multiple sclerosis by Wilkins, A, Scolding, N

“…Typically patients with multiple sclerosis (MS) experience acute episodes of neurological dysfunction, which recover followed, at a later stage, by slow and…”
Get full text

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort by COSSBURN, M, PACE, A. A, PICKERSGILL, T, BEN-SHLOMO, Y, COLES, A, ROBERTSON, N. P, JONES, J, ALI, R, INGRAM, G, BAKER, K, HIRST, C, ZAJICEK, J, SCOLDING, N, BOGGILD, M

Get full text